Skip to main content
UCL Ventures Navigate back to homepage
Find your Business Manager

Main navigation

  • Your route to market

    Your route to market

    We guide UCL academics, researchers and clinicians to get their research to market.

    Disclose an idea
    • Getting started An introduction to commercialisation and next steps
    • Our collaborative approach How we work with you to get to market
    • What you can expect Demystifying the process of commercialisation
    • Options to move forwards Explore the different pathways to market
      • Protect your idea
      • Create a company
      • Licensing your invention
      • Routes to social impact
    • Funding & support The financial and practical help that we can offer
      • Help managing your project
      • Training & tools
      • Common questions
  • Explore innovations

    Explore innovations

    Our portfolio and technologies span AI and quantum, to gene therapies to consumer products.

    • Current page: Spinout portfolio Browse our portfolio of spinout companies, based on UCL research
    • Our expertise & pipeline The sectors we span and therapeutics in development
    • Social Ventures Ventures driving impact in communities
    • License a technology Opportunities & collaborations with UCL's world-class research
  • Global impact

    Global impact

    How UCL research is changing the way the world lives, works and thrives.

    • Inspiring stories Real-world impact and successes, supported by UCL Ventures
    • Impact Report Our annual report showcases how UCL research is going beyond the university
    • Supporting innovation at UCL Understand our role in the innovation ecosystem
  • Investors & business

    Investors & business

    Opportunities for collaboration across UCL's world-class research.

    • Why partner with UCL Ventures With over 30 years in commercialisation, we have a strong track record
    • Our portfolio View our spinout companies across all sectors
  • News & events

    News & events

    The latest news and events from our team and portfolio.

    • News & views Stay up to date with the latest insights and announcements
    • Events Where you can find us across UCL and external events
  • Get in touch

    Get in touch

    Contact our team of experts for all your queries and needs.

    • Speak to the team Choose your enquiry type to reach the right team
Find your Business Manager

EpilepsyGTx

This UCL Ventures spinout focuses on cutting-edge treatments for focal refractory epilepsy.

3d rendered image of neuron cell network on black background

Breadcrumb trail

  1. Home
  2. Spinout portfolio
  3. EpilepsyGTx

EpilepsyGTx is a late preclinical-stage biotech, developing cutting-edge gene therapies that will transform the management of focal refractory epilepsy (FRE).

The spinout's goal is to make patients with FRE seizure-free. 

Epilepsy is one of the most common neurological diseases, affecting over 50 million people worldwide (WHO). Focal epilepsy is a group of disorders in which patients experience seizures that arise from a specific part of the brain, while refractory epilepsy occurs when seizures persist despite trials of at least two tolerated and appropriately chosen antiseizure treatments.

Approximately one in five patients with epilepsy has focal refractory epilepsy.  

The mortality in people with refractory epilepsy is four times higher than in the general population. In the UK alone, approximately 1,000 epilepsy-related deaths are recorded each year. The hallmark symptom of FRE is recurrent and unpredictable seizures, which can cause injury and become life-threatening. 

People with epilepsy often struggle with anxiety, depression, and the social stigma associated with their disease, and their professional life is severely restricted.

The EpilepsyGTx journey so far: 

  • 2024: EpilepsyGTx raised $10 million seed funding  
  • 2025: A $33 million Series A followed in 2025

 

The Epilepsy GTx team
The EpilepsyGTx team from UCL: Prof Stephanie Schorge; Prof Dimitri Kullmann; Prof Matthew Walker; Prof Gabriele Lignani,  

Our people

Team

No results found, try another search term.

Eileen McQuillan

Executive Assistant

Eileen joined the business in 2004, bringing with her a strong foundation in retail management and a customer-focused approach. Over the years, she has built extensive experience supporting senior leadership, with a reputation for reliability, discretion, and meticulous attention to detail. In her role, she plays a central part in coordinating strategic priorities, managing complex schedules, and ensuring the smooth running of day-to-day operations.

Eileen is known for her proactive mindset and ability to build trusted relationships across the organisation.

Outside of work, Eileen enjoys travelling and exploring new cultures, along with spending time at live music events and the theatre. She also has a passion for discovering great places to eat, whether locally or further afield.

  • LinkedIn

Dr. Eleanor Barlow

Associate Business Manager

Dr Barlow is part of the Physical Sciences & Engineering team, supporting the translation of academic research within the deep tech space into commercial opportunities. She works with UCL researchers to identify and develop innovative technologies, helping bring them closer to real-world application.

Eleanor holds a first-class MChem degree from the University of Liverpool, where her master’s research focused on the synthesis and characterisation of Porous Organic Cages (POCs) using both batch and flow approaches. During her degree, she worked in 3M’s Automotive Aftermarket Division, gaining experience in applied research and development. She recently completed her PhD within the Centre of Excellence in Long-acting Therapeutics, developing solid injectables of solid drug nanoparticles for long-acting drug delivery.

Eleanor combines a strong technical background with a keen interest in bridging academia and industry to enable the development and commercialisation of impactful technologies.

  • LinkedIn
  • Book a meeting

Elizabeth Parker

Financial Controller

Elizabeth worked at KPMG and has broad financial experience ranging from audit to risk and investment management, before joining us in 2017. As well as being a qualified accountant, she holds the Chartered Institute for Securities and Investment Diploma and has a BA (Hons) in French & German from Exeter University.

Emma Alam

Head of Marketing

Emma leads a team that delivers campaigns to drive growth, enhance reputation, and build strategic partnerships. She oversees marketing strategy across brand management, digital transformation, events, and engagement.

A Chartered Marketer with the Chartered Institute of Marketing (CIM) and holding a degree in Marketing, Emma has extensive experience in brand strategy, digital transformation, and stakeholder engagement across innovation, tech, and life sciences. She excels at turning complex ideas into clear, compelling narratives that resonate with diverse audiences. Her approach blends creative insight with data-driven strategy to achieve measurable results.

Passionate about connecting research with real-world impact, Emma supports UCL Ventures’ mission to transform ideas into solutions for global challenges.

  • LinkedIn

Faye Redman

Accounts Assistant

Faye transitioned from a varied role in primary education that included admissions, finance, and PA duties into the UCL Ventures team.

She now supports the finance team as an accounts assistant
with a particular focus on purchasing, where her strong organisational skills and accuracy support efficient financial operations. Alongside her role, Faye is strengthening her technical capabilities through her AAT studies.

Gemma Jackson

Head of Facilities & Office Administration

Gemma is responsible for leading workplace operations, facilities management, health and safety, and senior leadership support, while also developing and managing the administrative support function across the organisation.

With extensive management experience across multiple sectors, Gemma also plays a key role in supporting governance and leadership activity and ensuring the organisation is well supported. She joined us in 2013.

Hamish Bennett

General Counsel & Company Secretary

Hamish is part of the senior management team and lead the UCL Ventures legal team.

He has a strong commercial and university background, with over 20 years of experience in the life sciences
sector. Hamish began his career at Slaughter and May, gaining corporate, IP, and commercial law experience.

He then worked at Oxford and Cambridge, supporting university spinouts and early-stage growth companies. He has worked at BTG Plc as a Senior Legal Adviser; Mundipharma as Principal European Legal Adviser, handling global in-licensing and commercial partnerships; Eli Lilly as General Counsel for Northern Europe; and lastly as Joint Venture Director and Head of Legal, EMEA, at Kyowa Kirin International.

Hannah Harman

Senior Administrator

Hannah is a Senior Administrator with 10+ years’ experience in executive support and office operations. She is highly organised and proactive, with a passion for wellbeing and organising team events.

  • LinkedIn

Dr. Harriet Story (away from office)

Senior Business Manager

Dr Story joined us in 2019, covering the UCL School of Pharmacy, the Institute of Liver and Digestive Health, and the Centre for Rheumatology. She spent time co-representing the joint interests of UCL Ventures and Cancer Research UK as a cancer specialist, but is now solely a UCL Ventures employee.

Harriet joined us from Imperial Innovations, where she provided intellectual property and commercialisation services to four partner NHS Trusts: Imperial College Healthcare NHS Trust, Royal Brompton & Harefield NHS Foundation Trust, Chelsea and Westminster Hospital NHS Foundation Trust and London North West University Healthcare NHS Trust.

Prior to her career in technology transfer, she worked on a drug discovery project at CRUK’s Therapeutic Discovery Labs (TDL, previously known as CRT) and completed her interdisciplinary PhD at UCL with applications in cancer imaging and treatment.

  • « First
  • ‹ Previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Next ›
  • Last »
EpilepsyGTx logo

Team

Professor Dimitri Kullman

Chief Scientific Officer; Scientific Founder

He is part of the Queen Square Institute of Neurology.

  • UCL Profile

Professor Stephanie Schorge

Scientific Founder

Stephanie is the Sophia Jex-Blake Professor of Neuroscience at UCL and the Head of the Research Department of Neuroscience, Physiology and Pharmacology (NPP). She has been at UCL since 1999.

Prof Matthew Walker (UCL Institute of Neurology)

Prof Gabriele Liagnani (UCL Institute of Neurology)

Caitriona O'Rourke

Dr. Caitriona O'Rourke (Away from office)

Senior Business Manager

Dr O’Rourke joined us in 2018, having worked as a research associate within UCL on several diverse life science / pharmaceutical research projects covering the areas of tissue engineering, drug delivery, regenerative medicine, biomaterials and stem cell biology.

Caitriona holds a PhD in tissue engineering from the Open University and a MSc in neuropharmacology from the National University of Galway, Ireland.

UCL Ventures footer

About UCL Ventures

  • Our people
  • What we do
  • Who we are
  • Our culture

Forms & Resources

  • Publications and downloads

Accreditations

  • Cyber essentials
    cyber essentials logo
  • Living wage
    living wage employer logo
UCL Ventures

UCL Ventures Limited (Company Registration No: 02776963) is a wholly-owned subsidiary of University College London. 

Registered office: 
University College London
Gower Street
London
WC1E 6BT

UCL social media menu

  • Link to Linkedin
Back to top

Legal

  • Cookie policy
  • Freedom of information
  • Privacy policy
  • Rules of website use

© 2026 UCL Ventures Limited